1. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): non-small cell lung cancer (version 1.2019). 2018. http://www.nccn.org . Accessed 07 Oct 2018.
2. Ellis PM, Coakley N, Feld R, et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr Oncol. 2015;22(3):e183–215.
3. Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013;11(2):161–9.
4. US FDA. Vizimpro® (dacomitinib) tablets: US prescribing information. 2018. http://www.fda.gov . Accessed 07 Oct 2018.
5. Pfizer. U.S. FDA approves Vizimpro® (dacomitinib) for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer [media release]. 2018. http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer . Accessed 07 Oct 2018.